| Expression pattern: |
UP |
| Associated gene: |
FTO, AGO2 |
| Associated microRNA: |
hsa-miR-1322 |
| Biological function: |
promotes adipogenesis and triglyceride/lipid droplet accumulation |
| Molecular mechanism: |
ceRNA mechanism: circMAPK9 sponges hsa-miR-1322 to relieve repression of FTO |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (not specified) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; RNase R Treatment; Sanger Sequencing; divergent primers PCR; FISH / smFISH; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; Western Blot; Oil Red O Staining; ELISA; In Vivo Animal Model; H&E Staining; ROC Analysis; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
circMAPK9 expression level was higher in obese VATs than in lean VATs, was positively associated with BMI, and showed diagnostic value by ROC analysis (AUC = 0.7657). |
| Description: |
In obesity (VATs), circMAPK9 is up-regulated and positively correlates with BMI. It promotes adipogenesis by sponging hsa-miR-1322 in the cytoplasm, thereby relieving repression of FTO and increasing adipogenic markers and lipid accumulation; it also shows diagnostic value by ROC analysis. |
| Confidence score: |
0.8632 |